SCHEMBL8526291

SCHEMBL8526291

COC(=O)c1cc2c(cc1Cl)NCC2

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR2A P28223 1/20 0.41
HTR2C P28335 1/20 0.41
DRD2 P14416 1/20 0.40
DRD4 P21917 1/20 0.40
GAA P10253 1/20 0.38
MEN1 O00255 2/20 0.37
LMNA P02545 2/20 0.37
KMT2A Q03164 2/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
MAPT P10636 2/20 0.36
ABL1 P00519 1/20 0.36
NR4A2 P43354 4/20 0.35
HTT P42858 1/20 0.35
NPSR1 Q6W5P4 1/20 0.35
ALDH1A1 P00352 1/20 0.35
TSHR P16473 1/20 0.35
PYGL P06737 1/20 0.35
JAK2 O60674 2/20 0.35
JAK3 P52333 2/20 0.35
SLC6A3 Q01959 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14539708 0.83 MAPT (0.41) DRD2DRD4GAAMEN1KMT2A
SCHEMBL13954896 0.81 DRD2 (0.44) DRD2DRD4MEN1LMNAKMT2A
SCHEMBL5200021 0.77 ALDH1A1 (0.44) DRD2DRD4SMN1; SMN2MAPTALDH1A1
SCHEMBL29923872 0.76 DRD2 (0.40) DRD2DRD4SMN1; SMN2MAPTALDH1A1
SCHEMBL22226381 0.75 ALDH1A1 (0.48) GAAMEN1LMNAKMT2ASMN1; SMN2
SCHEMBL3574814 0.74 PYGL (0.47) MEN1LMNAKMT2ASMN1; SMN2MAPT
SCHEMBL28834758 0.74 MAPT (0.52) MEN1KMT2ASMN1; SMN2MAPTHTT
SCHEMBL70011 0.74 GAA (0.58) GAAMEN1LMNAKMT2ASMN1; SMN2
SCHEMBL8115538 0.74 SERPINH1 (0.43) GAAMEN1KMT2ASMN1; SMN2MAPT
SCHEMBL25072882 0.74 GAA (0.46) GAAMEN1LMNAKMT2ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7488744-B2 Indole-type derivatives as inhibitors of p38 kinase SCIOS, INC. (US) 2009-02-10 US disclosed
US-20070232617-A1 INDOLE-TYPE DERIVATIVES AS INHIBITORS OF P38 KINASE SCIOS, INC. (US) 2007-10-04 US disclosed
US-7220763-B2 Indole-type derivatives as inhibitors of p38 kinase SCIOS, INC. (US) 2007-05-22 US disclosed
US-5834494-A SEROTONIN 5HT2B/2C RECEPTOR ANTAGONISTS; CNS NERVOUS SYSTEM AND PSYCHOLOGICAL DISORDERS; IRRITABLE BOWEL SYNDROME SMITHKLINE BEECHAM P.L.C. (GB) 1998-11-10 US disclosed
EP-0707581-B1 INDOLINE DERIVATIVES AS 5HT2C ANTAGONISTS SMITHKLINE BEECHAM PLC (GB) 1997-02-26 EP disclosed
EP-0707581-A1 INDOLINE DERIVATIVES AS 5HT 2C? ANTAGONISTS SMITHKLINE BEECHAM PLC (GB) 1996-04-24 EP disclosed
WO-1995001976-A1 INDOLINE DERIVATIVES AS 5HT2C ANTAGONISTS SMITHKLINE BEECHAM PLC (GB) 1995-01-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070232617-A1 INDOLE-TYPE DERIVATIVES AS INHIBITORS OF P38 KINASE MAPK1, MAPKAPK2, MAPKAPK5 HTR2A 573/4885HTR2C 492/4885DRD2 1265/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.